Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775210 | 0.77 | CHRM1 (0.39) | CHRM1CHRNB2CHRNA4PRKCZPIK3CD | |
| SCHEMBL30775173 | 0.76 | SYK (0.50) | CHRM1CHRNB2CHRNA4PRKCZKCNH2 | |
| SCHEMBL30775337 | 0.76 | IRAK4 (0.45) | CHRM1CHRNB2CHRNA4PRKCZKCNH2 | |
| SCHEMBL30775180 | 0.74 | CHEK1 (0.41) | CHRM1CHRNB2CHRNA4PRKCZCHEK1 | |
| SCHEMBL30775327 | 0.71 | CHRM1 (0.39) | CHRM1CHRNB2CHRNA4PRKCZCHEK1 | |
| SCHEMBL29003837 | 0.71 | CHRNB2 (0.46) | CHRM1CHRNB2CHRNA4PRKCZKCNH2 | |
| SCHEMBL30422988 | 0.71 | CHRNB2 (0.46) | CHRM1CHRNB2CHRNA4PRKCZKCNH2 | |
| SCHEMBL29003833 | 0.71 | CHRNB2 (0.46) | CHRM1CHRNB2CHRNA4PRKCZKCNH2 | |
| SCHEMBL7889387 | 0.70 | CHRNB2 (0.54) | CHRM1CHRNB2CHRNA4PRKCZ | |
| SCHEMBL4102786 | 0.70 | CHRNB2 (0.54) | CHRM1CHRNB2CHRNA4PRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | CHRM1 4823/4885CHRNB2 3816/4885CHRNA4 4788/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CHRM1 4823/4885CHRNB2 3816/4885CHRNA4 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.